Tag : MUSCLE-INVASIVE BLADDER CANCER

The phase 2 SAKK 06/19 study demonstrated that adding intravesical recombinant BCG (rBCG) to perioperative cisplatin/gemcitabine + atezolizumab achieved a high pathological complete response (pCR) rate in patients with muscle-invasive bladder cancer (MIBC) while maintaining a feasible and tolerable safety profile, supporting further evaluation of this multimodal strategy in randomized clinical trials.